COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

SARS-CoV-2 Serology Reimbursement Rates Posted

Centers for Medicare & Medicaid Services
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

New CMS guidelines outline compensation rates for SARS-CoV-2 serology tests for clinical laboratories and pathology groups.

The Centers for Medicare and Medicaid Services (CMS) released reimbursement rates for SARS-CoV-2 serology testing on May 19, 2020. CMS announced at the end of April that it would cover SARS-CoV-2 serology testing costs but had not set reimbursement rates.

The American Medical Association (AMA) created two Current Procedural Terminology (CPT) codes on April 10, 2020, for SARS-CoV-2 serology testing. Code 86769 is for SARS-CoV-2 serology tests that use multiple-step methods, while code 86328 is used for serology testing with a single-step method immunoassay.

Details of the announcement by Medicare administrative contractor (MAC) jurisdiction can be found through the May 19, 2020, release that is detailed at this link for the two codes below and more:

  • $42.13 for code 86769
  • $45.23 for code 86328

American Clinical Laboratory Association President Julie Khani released a statement following the CMS announcement, explaining that these rates “will encourage a broad cross section of laboratories to rapidly scale up capacity for accurate and reliable serologic testing for SARS-CoV-2.”

Related Resources:

Medicare Administrative Contractor (MAC) COVID-19 Test Pricing May 19, 2020

ACLA Statement on Medicare Reimbursement Rate For Serologic Testing


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group